TY - JOUR
T1 - Severely compromised supply of patch test allergens in Europe hampers adequate diagnosis of occupational and non-occupational contact allergy. A European Society of Contact Dermatitis (ESCD), European Academy of Allergy and Clinical Immunology (EAACI), European Academy of Dermatology and Venereology (EADV) task forces ‘Contact Dermatitis’ and ‘Occupational Skin Disease’ position paper
AU - John, Swen Malte
AU - Bonertz, Andreas
AU - Zimmer, Julia
AU - Aerts, Olivier
AU - Bauer, Andrea
AU - Bova, Maria
AU - Brans, Richard
AU - Del Giacco, Stefano
AU - Dickel, Heinrich
AU - Corazza, Monica
AU - Crépy, Marie Noëlle
AU - Gallo, Rosella
AU - Garcia-Abujeta, Jose Luis
AU - Giménez-Arnau, Ana Maria
AU - Klimek, Ludger
AU - Lepoittevin, Jean Pierre
AU - Ljubojević Hadžavdić, Suzana
AU - Matura, Mihaly
AU - Mortz, Charlotte Gotthard
AU - Özkaya, Esen
AU - Pesonen, Maria
AU - Raison-Peyron, Nadia
AU - Rustemeyer, Thomas
AU - Skudlik, Christoph
AU - Spiewak, Radoslaw
AU - Stingeni, Luca
AU - Suomela, Sari
AU - Symanzik, Cara
AU - Taylor, James
AU - Torres, Maria
AU - Uter, Wolfgang
AU - White, Ian
AU - Wilkinson, Mark
AU - Mahler, Vera
AU - Johansen, Jeanne Duus
PY - 2024/8
Y1 - 2024/8
N2 - Patch testing is the only clinically applicable diagnostic method for Type IV allergy. The availability of Type IV patch test (PT) allergens in Europe, however, is currently scarce. This severely compromises adequate diagnostics of contact allergy, leading to serious consequences for the affected patients. Against this background, the European Society of Contact Dermatitis (ESCD) has created a task force (TF) (i) to explore the current availability of PT substances in different member states, (ii) to highlight some of the unique characteristics of Type IV vs. other allergens and (iii) to suggest ways forward to promote and ensure availability of high-quality patch testing substances for the diagnosis of Type IV allergies throughout Europe. The suggestions of the TF on how to improve the availability of PT allergens are supported by the ESCD, the European Academy of Allergy and Clinical Immunology, and the European Academy of Dermatology and Venereology and intend to provide potential means to resolve the present medical crisis.
AB - Patch testing is the only clinically applicable diagnostic method for Type IV allergy. The availability of Type IV patch test (PT) allergens in Europe, however, is currently scarce. This severely compromises adequate diagnostics of contact allergy, leading to serious consequences for the affected patients. Against this background, the European Society of Contact Dermatitis (ESCD) has created a task force (TF) (i) to explore the current availability of PT substances in different member states, (ii) to highlight some of the unique characteristics of Type IV vs. other allergens and (iii) to suggest ways forward to promote and ensure availability of high-quality patch testing substances for the diagnosis of Type IV allergies throughout Europe. The suggestions of the TF on how to improve the availability of PT allergens are supported by the ESCD, the European Academy of Allergy and Clinical Immunology, and the European Academy of Dermatology and Venereology and intend to provide potential means to resolve the present medical crisis.
KW - allergen provocation test
KW - European Pharmacopoeia
KW - marketing authorisation
KW - patch test
KW - regulatory framework
KW - skin test allergens
KW - Type IV allergy
KW - Humans
KW - Europe
KW - Patch Tests/methods
KW - Advisory Committees
KW - Societies, Medical
KW - Dermatitis, Allergic Contact/diagnosis
KW - Allergens/adverse effects
KW - Dermatitis, Occupational/diagnosis
U2 - 10.1111/cod.14580
DO - 10.1111/cod.14580
M3 - Journal article
C2 - 38812248
AN - SCOPUS:85194890445
SN - 0105-1873
VL - 91
SP - 91
EP - 103
JO - Contact Dermatitis
JF - Contact Dermatitis
IS - 2
ER -